by Segment Analysis
The Charcot-Marie-Tooth Disease market is segmented into hereditary neuropathy with liability to pressure palsies (HNPP), hereditary motor and sensory neuropathy (HMSN), and distal hereditary motor neuropathy. Among these, the hereditary motor and sensory neuropathy (HMSN) segment is expected to dominate the market over the forecast period. HMSN affects the peripheral nervous system by damaging the neurons that send signals to the muscles from the spinal cord and brain.
PEST Analysis
Political: Government agencies are increasing funding to support research activities for the treatment of rare diseases like Charcot-Marie-Tooth Disease.
Economic: The rising disposable income and increasing healthcare expenditure are driving the growth of the Charcot-Marie-Tooth Disease market.
Social: Growing awareness about rare diseases and their management through social media campaigns is positively impacting the market.
Technological: Advancements in gene therapy and development of novel therapeutic molecules are providing new opportunities for CMT treatment.
The global Charcot-Marie-Tooth Disease Market Demand is estimated to be valued at US$ 793.9 Mn in 2023 and is expected to exhibit a CAGR of 23.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Key Takeaways
The North American region is expected to dominate the market during the analysis period owing to the growing cases of CMT in the US and Canada. Key players operating in the Charcot-Marie-Tooth Disease are Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. The market players are continuously focusing on R&D activities to develop novel therapeutics for better disease management.
Regional analysis
The North American region is expected to witness the fastest growth in the Charcot-Marie-Tooth Disease market during the forecast period. This is attributed to the growing prevalence of CMT in countries like the US and Canada. According to the National Organization for Rare Disorders (NORD), CMT affects approximately 1 in 2,500 people in the US.
Key players
Key players operating in the Charcot-Marie-Tooth Disease market are Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. The key players are majorly focusing on developing therapies targeting genetic mutations responsible for CMT such as gene therapy drugs using AAV vectors.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
